Effective immunization of mice against cutaneous leishmaniasis using an intrinsically adjuvanted synthetic lipopeptide vaccine

Keyphrases

• Cutaneous Leishmaniasis 100%
• Peptide Vaccine 100%
• Adjuvanted 100%
• Synthetic Lipopeptide 100%
• Effective Immunization 100%
• Gp63 100%
• Immunization 66%
• Cellular Immunity 66%
• Amino Acids 33%
• Amino-terminus 33%
• Cysteine 33%
• Interleukin-10 33%
• Granulocyte Colony-stimulating Factor (G-CSF) 33%
• Proliferative Response 33%
• Interleukin-4 (IL-4) 33%
• Leishmania Major 33%
• Murine Model 33%
• Interleukin-2 33%
• Safety Efficacy 33%
• Parasitic Diseases 33%
• Leishmaniasis 33%
• Surface Glycoprotein 33%
• T Cell Epitope 33%
• Lipopeptide 33%
• Viral Disease 33%
• Vaccine Development 33%
• Disease Exacerbation 33%
• Cutaneous Lesions 33%
• Cytokine Response 33%
• Splenic Cells 33%
• CBA Mice 33%

Immunology and Microbiology

• Cutaneous Leishmaniasis 100%
• Peptides 100%
• Adoptive Immunity 66%
• Amino Terminal Sequence 33%
• T Cell 33%
• Secretion (Process) 33%
• Viral Disease 33%
• Granulocyte Macrophage Colony-Stimulating Factor 33%
• Epitope 33%
• Interleukin 10 33%
• Interleukin 4 33%
• Leishmaniasis 33%
• Leishmania Major 33%
• Glycoprotein 33%
• Splenocyte 33%
• Interleukin 2 33%
• Cytokine Response 33%
• CBA Mouse 33%
• Amino Acid 33%
• Cysteine 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Skin Leishmaniasis 100%
• Lipopeptide 100%
• Table Salt 66%
• Virus Infection 33%
• Amino Acid 33%
• Cytokine 33%
• Epitope 33%
• Interleukin 2 33%
• Glycoprotein 33%
• Skin Defect 33%
• Cysteine 33%
• Disease Exacerbation 33%
• Leishmania Major 33%
• Interleukin 4 33%
• Leishmaniasis 33%
• Granulocyte Macrophage Colony Stimulating Factor 33%
• Interleukin 10 33%
• CBA Mouse 33%